NCT04835961View on ClinicalTrials.gov

AdditioN of Fixed Dose Combination (FDC) Of Budesonide/Formoterol Via Elpenhaler® Device in Greek Patients With asThma accΟrding to Standard Clinical Practice.

CompletedOBSERVATIONAL
Enrollment

1,037

Participants

Timeline

Start Date

May 1, 2021

Primary Completion Date

July 1, 2022

Study Completion Date

July 1, 2022

Conditions
Asthma
Interventions
OTHER

Maintenace and As needed

This study will record the use of budesonide / formoterol either as maintenance treatment or / or as needed according to standard clinical practice and at the discretion of the treating physician.

Trial Locations (1)

Unknown

Sotiria Hospital, Athens

Sponsors
All Listed Sponsors
lead

Elpen Pharmaceutical Co. Inc.

INDUSTRY